Voornaam, your FORCE March Hereditary Cancer Update

Get Support Donate Get Involved Attend Local Event

Teri Woodhull Empowerment Award Honoree: Susan Feinberg

FORCE congratulates Susan Feinberg, the 2021 Teri Woodhull Empowerment Award Honoree. Susan is the first recipient of the award named in honor of former FORCE Board of Director President, Teri Woodhull. We invite you to join us in recognizing Susan’s many contributions to the hereditary cancer community and learn more about the award.
Read more

COVID vaccine guidance for people living with cancer

People living with cancer are at increased risk of complications from COVID-19. Vaccination is recommended for most cancer patients. Read more on recently issued COVID vaccination guidelines for people with cancer.
View our XRAY article

Video addresses COVID-19 vaccines for people with inherited mutations

Matt Yurgelun, MD, and Allison Kurian, MD, medical experts in hereditary cancer and FORCE advisory board members, address the safety of new COVID-19 vaccines for people with inherited mutations.
Watch our video

FDA approves a new oral therapy for advanced prostate cancer

The FDA recently approved Orgovyx, a new oral hormone therapy to treat advanced prostate cancer. Because Orgovyx is a pill, its approval may help some patients eliminate clinic visits for hormone therapy injections or implants.
View our XRAY article

Our growing community shares empowering thoughts

Hear from members of the growing FORCE community – those facing hereditary breast, ovarian, pancreatic, prostate, colorectal and endometrial cancers as a result of a BRCA, ATM, PALB2, CHEK2, PTEN or other inherited gene mutation and those with Lynch syndrome – about how knowing their genetic status empowered them to protect their health and help others.

Watch our 1-minute video

Volunteer spotlight: Sivan Schondorf

Thank you, Sivan, for empowering others to become advocates for themselves. We are incredibly grateful that you decided to continue the support your parents started as Chicago Leaders, educating people on the generational impact hereditary cancer can have on families. You are a true inspiration! If you are interested in making a difference, please complete a VolunteerFORCE application today.

FORCE survey for people living with metastatic breast cancer

Do you have metastatic breast cancer? FORCE together with Susan G. Komen, METAvivor and researchers at the University of South Florida want to learn about your information and support needs. Please take this short, 15 min survey.
Take the survey

Obtain virtual support

You are not alone! Connect with peers and trained volunteers who understand the decisions you face from the comfort of your home. ASL available, email [email protected].

Navigation portals connect people to information, research and support resources

FORCE has new portal pages with links to information, research and support resources. Find relevant information organized by topic, cancer type or gene mutation:

Find hereditary cancer studies and participate in research!

Please visit our Search and Enroll Tool to find and participate in research studies enrolling patients like you. You can also view a list of surveys, registries and other online studies that you can participate in from home.

Clinical trials and research studies need participants

The research studies below are enrolling people with, or at high risk for, hereditary cancer.

TALAPRO-2, A Metastatic Castration-resistant Prostate Cancer Research Study

Living with advanced prostate cancer can feel overwhelming. TALAPRO-2 is a clinical trial investigating a potential treatment for patients with metastatic castration-resistant prostate cancer (mCRPC) who have DNA damage repair (DDR) deficiency. To learn more, visit the TALAPRO-2 website.
Learn more

Research study on family communication

If you have a BRCA mutation, are age 18+, have an email, and have access to the internet, you can participate in a study about the usefulness of a new FORCE Family Communication Guide and a video that was developed by genetics experts at The Ohio State University. Participants will be randomly assigned to receive the guide only or the guide plus the video. You will be asked to complete electronic surveys before and after you receive the resources; participants who complete the surveys will be offered up to $15 in Amazon gift cards.
Learn more

Genetic vaccine for the treatment of MSI-H colorectal, gastric and gastro-esophageal junction tumors

The goal of this cancer treatment study is to find the best dose and learn how safe and effective this cancer vaccine is for treating advanced colorectal, gastric and gastro-esophageal junction tumors that test positive for the biomarkers MSI-High or dMMR.
Learn more about the study

Talazoparib for people with metastatic breast cancer who have acquired (somatic) BRCA mutations

This study is enrolling individuals with metastatic breast cancer (triple-negative or hormone receptor positive, HER2 negative breast cancer) who have a BRCA1/2 mutation found in a liquid biopsy (cell-free DNA) but do not have a known inherited BRCA1/2 mutation to see if talazoparib is an effective treatment. This study is also using liquid biopsies to track treatment response and resistance. The study is open at Massachusetts General Hospital, and will also open soon at the University of California San Francisco and 5 other academic centers in the U.S.
Learn more

SOROCk study for women with a BRCA1 mutation

Women with a BRCA1 mutation ages 35-50 at risk for ovarian cancer are eligible for the SOROCk study. SOROCk will determine if removal of the fallopian tubes alone can reduce the risk of ovarian cancer nearly as much as removing both the ovaries and fallopian tubes. Preserving the ovaries will prevent surgically-induced menopause. The study will also examine quality of life.
Learn more

Pain anxiety in cancer survivors

Are you a cancer survivor who received a cancer diagnosis at 18 years of age and older? If so, you may qualify to participate in the study "Pain Anxiety in Cancer Survivors”! You can participate by using your personal computer from home. We are investigating the relation of childhood adversity, pain, and fear of cancer recurrence. Participation involves completing a 15-minute computerized survey online from your home computer. No compensation is being offered for participation in this research study.
Learn more

A study of melphalan, BCNU, vitamin B12b, Vitamin C, and stem cell infusion in people with advanced pancreatic cancer and BRCA mutations

The purpose of this study is to see whether the combination of melphalan, BCNU, vitamin B12b, and vitamin C, followed by autologous (self) bone marrow stem cell infusion, is safe and effective for treating patients with advanced pancreatic cancer who have a BRCA1 and/or BRCA2 gene mutation.
Learn more

Denosumab and mammographic density in premenopausal women with dense breasts

This study is looking at the effect of denosumab on breast density of premenopausal women who have dense breasts. Denosumab is an FDA-approved medication for osteoporosis and to prevent fractures in cancer patients with bone metastases. This study could help identify new ways to prevent breast cancer in younger women.
Learn about the study

Study for people with unexpected genetic results

Did you receive an unexpected genetic test result related to cancer risk? A new study is recruiting people who had genetic testing done for some other reason and received results related to their cancer risks. The goal of this study is to learn what people think about, and how they use results like this.
Learn more about the study

A study to evaluate rucaparib in patients with solid tumors and with deleterious mutations in HRR genes (LODESTAR)

The LODESTAR study is evaluating the response of the PARP inhibitor rucaparib in people with advanced solid tumors (including breast, ovarian, pancreatic, prostate and other cancers) who have an inherited or acquired mutation in any of the following genes: BRCA1, BRCA2, PALB2, RAD51C, RAD51D, BARD1, BRIP1, FANCA, NBN, RAD51 or RAD51B.
Learn more about LODESTAR

IMMray™ PanCan-d Test for early detection of pancreatic cancer in high-risk groups

Pilot study of denosumab in BRCA1 or BRCA2 mutation carriers scheduling risk-reducing Salpingo-Oophorectomy

Are you a BRCA1 or BRCA2 mutation carrier scheduled to have your fallopian tubes and ovaries removed? Learn about an opportunity to enroll in a clinical trial looking at the effects of denosumab on the ovaries, fallopian tubes, and uterus (for women getting a hysterectomy) of women with a BRCA1 or BRCA2 mutation. Denosumab is an FDA-approved injectable medication that is used to treat osteoporosis and to prevent fractures in cancer patients with bone metastases. The eventual goal is to understand if denosumab may be used to reduce the risk of ovarian cancer in women with a BRCA1 or BRCA2 mutation.
Learn more

Screening for men at high genetic risk for prostate cancer

CALLING ALL MEN WITH A BRCA MUTATION, A LYNCH SYNDROME MUTATION or one of the other mutations listed below! The National Institutes of Health has a clinical trial for men at high genetic risk for prostate cancer. This is trial is for men without prostate cancer, ages 30 to 75, who have tested positive for Lynch syndrome (MLH1, MSH2, MSH6, PMS2, EPCAM) or BRCA1, BRCA2, HOXB13, ATM, NBN, TP53, BRIP1, CHEK2, PALB2, RAD51C, RAD51D, FANCA. The trial involves screening MRI of the prostate every two years and biopsy of the prostate if the MRI is abnormal. There is no cost for travel or study-related tests.
Learn more about the study

A study in advanced breast cancer patients with BRCA 1/2 mutations evaluating olaparib alone or in combination with atezolizumab

This is a study for women or men who have been diagnosed with advanced breast cancer with a BRCA 1/2 mutation. The goal of this study is to look at whether giving the DNA damage repair inhibitor (PARP inhibitor) olaparib (Lynparza) in combination with the immunotherapy atezolizumab (Tecentriq) improves outcomes for patients compared to olaparib alone.
Learn more about the study

CheckMate-9KD

Menopause and cognitive difficulty study

Did you know undergoing surgically or chemically induced menopause could put you at risk for cognitive difficulties? Our study seeks to determine the effectiveness of a stimulant drug called Vyvanse on the cognitive functioning of women who experience executive functioning difficulties following surgically induced menopause. For more information, please contact our team.

Learn more about IMPRES

GENTleMEN Study: Genetic Testing for Men with Metastatic Prostate Cancer

The goal of this research study is to determine if online genetic education and testing with online telephone genetic counseling is an acceptable method of delivering genetic testing to men with metastatic prostate cancer.

This study involves undergoing genetic counseling and genetic testing for inherited cancer risk.

Learn more about the study

Athena- rucaparib and novolumab for maintenance in ovarian cancer

ATHENA is a study for women who are newly diagnosed with ovarian cancer. ATHENA is looking at whether maintenance therapy with a PARP inhibitor and/or immunotherapy improves outcomes for women who have completed front-line ovarian cancer treatment.

Learn more about ATHENA

Genetic Education for Men (GEM) Study

The Genetic Education for Men (GEM) study, is a clinical trial evaluating educational tools for men from families in which a BRCA1/2 gene mutation has been identified. In order to identify untested men from BRCA1/2 families, we are seeking women who have received positive BRCA1/2 test results and have at least one untested male relative.

Learn more about the GEM study

ARIEL4- ovarian cancer

ARIEL4 is a treatment study for women with relapsed, high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who have a BRCA1 or BRCA2 mutation. ARIEL4 is designed to evaluate rucaparib against standard of care chemotherapy in women who have had at least two prior chemotherapy regimens. Visit the ARIEL4 Study page for more information.

More information on ARIEL4

TRITON3- prostate cancer

The purpose of TRITON3 is to determine how patients with metastatic castration-resistant prostate cancer, and an inherited BRCA1, BRCA2 or ATM gene mutation or tumor genetic deficiency respond to treatment with the PARP inhibitor rucaparib (Rubraca) compared to treatment with physician's choice of abiraterone acetate, enzalutamide, or docetaxel.

More information on TRITON3

FORCE®, FORCE FACING OUR RISK OF CANCER EMPOWERED®, JOINING FORCE AGAINST HEREDITARY CANCER®, PREVIVOR®, and the FORCE Ribbon Design are registered trademarks of FORCE- Facing Our Risk of Cancer Empowered, Inc. in the United States. Unauthorized reproduction or use of FORCE's trademarks is prohibited.